Summit Therapeutics Inc 6-K, filed Jun 23, 2020
Summit Therapeutics Inc. (SMMT)
6-K
2020-06-23
For: 2020-06-22
View Original
Added on
April 09, 2026
About this 6-K
Summit Therapeutics Inc filed this 6-K on June 23, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2020
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrant’s name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F x FORM 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On June 18, 2020, Glyn Edwards provided notice of his resignation as a member of the board of directors (the “Board”) of Summit Therapeutics plc (the “Company”), effective immediately. Mr. Edwards’ resignation was not related to any disagreement with the Company on any matter related to the Company’s operations, policies or practices.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SUMMIT THERAPEUTICS PLC | |||||||||||
| Date: June 22, 2020 | By: | /s/ Robert Duggan | |||||||||
| Robert Duggan | |||||||||||
| Chief Executive Officer | |||||||||||